View in EDS HTML Full Text PDF Full Text

Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.

Saved in:
Bibliographic Details
Title: Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
Authors: Gallo S; Pfizer Deutschland GmbH, Berlin, Germany., Charbonnel B; University of Nantes, Nantes, France., Goldman A; Pfizer Inc., Collegeville, Pennsylvania., Shi H; Pfizer Inc., New York, New York., Huyck S; Merck & Co., Inc., Kenilworth, New Jersey., Darekar A; Pfizer Ltd., Tadworth, UK., Lauring B; Merck & Co., Inc., Kenilworth, New Jersey., Terra SG; Pfizer Inc., Andover, Massachusetts.
Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2019 Apr; Vol. 21 (4), pp. 1027-1036. Date of Electronic Publication: 2019 Feb 14.
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 30614616
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gallo+S%22">Gallo S</searchLink>; Pfizer Deutschland GmbH, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Charbonnel+B%22">Charbonnel B</searchLink>; University of Nantes, Nantes, France.<br /><searchLink fieldCode="AU" term="%22Goldman+A%22">Goldman A</searchLink>; Pfizer Inc., Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Shi+H%22">Shi H</searchLink>; Pfizer Inc., New York, New York.<br /><searchLink fieldCode="AU" term="%22Huyck+S%22">Huyck S</searchLink>; Merck & Co., Inc., Kenilworth, New Jersey.<br /><searchLink fieldCode="AU" term="%22Darekar+A%22">Darekar A</searchLink>; Pfizer Ltd., Tadworth, UK.<br /><searchLink fieldCode="AU" term="%22Lauring+B%22">Lauring B</searchLink>; Merck & Co., Inc., Kenilworth, New Jersey.<br /><searchLink fieldCode="AU" term="%22Terra+SG%22">Terra SG</searchLink>; Pfizer Inc., Andover, Massachusetts.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100883645%22">Diabetes, obesity & metabolism</searchLink> [Diabetes Obes Metab] 2019 Apr; Vol. 21 (4), pp. 1027-1036. <i>Date of Electronic Publication: </i>2019 Feb 14.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100883645 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1463-1326 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214628902%22">14628902 </searchLink><i>NLM ISO Abbreviation: </i>Diabetes Obes Metab <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=30614616
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/dom.13631
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1027
    Titles:
      – TitleFull: Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gallo S
      – PersonEntity:
          Name:
            NameFull: Charbonnel B
      – PersonEntity:
          Name:
            NameFull: Goldman A
      – PersonEntity:
          Name:
            NameFull: Shi H
      – PersonEntity:
          Name:
            NameFull: Huyck S
      – PersonEntity:
          Name:
            NameFull: Darekar A
      – PersonEntity:
          Name:
            NameFull: Lauring B
      – PersonEntity:
          Name:
            NameFull: Terra SG
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2019 Apr
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-electronic
              Value: 1463-1326
          Numbering:
            – Type: volume
              Value: 21
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Diabetes, obesity & metabolism
              Type: main
ResultId 1